Anthem Biosciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Anthem Biosciences' recent management commentary indicates a constructive outlook despite a muted Q1 FY27, attributed to temporary shipment deferrals rather than a decline in demand. The company is focused on enhancing capacity utilization and commercializing its Semaglutide API, with a strong order book visibility of 60%. This aligns with Vista's forecast of revenue contraction, as the anticipated growth from late-stage pipeline projects may not materialize in the short term due to execution risks and regulatory timelines. The competitive landscape remains challenging, with pricing pressures impacting margins, yet Anthem's strategic investments in advanced manufacturing technologies and capacity expansion are expected to support long-term growth. The macro environment in India is supportive, but foreign institutional flows turning negative could pose risks. Over the next 12-24 months, key opportunities include the successful launch of new products and expansion of manufacturing capabilities, while watchpoints include regulatory approval timelines and customer concentration risks
Why We Like This Stock
- Strong order book visibility of 60% supports management's growth outlook
- Strategic investments in capacity expansion and advanced manufacturing technologies are expected to enhance long-term profitability
- Positive macroeconomic conditions in India provide a supportive backdrop for growth
Things To Watch Out For
- Revenue is expected to contract in the near term due to shipment deferrals and execution risks
- Margins are under pressure from competitive pricing dynamics in the CRDMO sector
- Regulatory approval timelines for new products pose risks to anticipated revenue growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,419 | 1,845 | 2,124 | 2,007 | 2,394 |
| Profit Before Tax (Cr.) | 477 | 657 | 848 | 777 | 933 |
| PBT Margin | 33.6% | 35.6% | 3992.5% | 38.7% | 39.0% |
| Net Profit (Cr.) | 351 | 475 | 600 | 551 | 661 |
| Earnings Per Share | 6.2 | 8.4 | 10.6 | 9.8 | 11.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ▲ Buy | 900 | 21-May-2026 |
| Citigroup | ▲ Buy | 870 | 06-Jun-2026 |
| Deven Choksey | ▲ Buy | 818 | 22-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 850 | 23-Jul-2026 |
Company Overview
Show Company Profile
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.